Bionime Corporation operates within the Diagnostic substances sector. In addition to historical fundamental analyses, the complete report available to purchase compares Bionime with three other companies in this sector in Taiwan: Cowealth Medical Holding Co Ltd (2017 sales of 3.04 billion Taiwanese Dollars [US$98.57 million] of which 96% was Depar. B(Sale Reagent&Other)), OK Biotech Co Ltd (1.23 billion Taiwanese Dollars [US$40.03 million] ), and Apex Biotechnology Corporation (1.80 billion Taiwanese Dollars [US$58.28 million] of which 58% was Test Strip).

Sales Analysis. During the year ended December of 2017, sales at Bionime were 1.82 billion Taiwanese Dollars (US$59.09 million). This is an increase of 4.6% versus 2016, when the company's sales were 1.74 billion Taiwanese Dollars. This was the third consecutive year of growth at Bionime.